A previous study indicated that miR-US4-1 encoded by HCMV in human plasma serves as a biomarker for predicting the efficacy of IFN-α treatment in chronic hepatitis B patients (70). The gene discussed is IFNA1; the disease is chronic hepatitis B virus infection.